Literature DB >> 15933063

Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.

Beate Schultheis, Richard Szydlo, François X Mahon, Jane F Apperley, Junia V Melo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15933063     DOI： 10.1182/blood-2005-01-0210

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

1.  CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.

Authors:  Juandong Wang; Tao Huang; Jianzhi Sun; Yuan Yu; Zhifang Liu; Wenjuan Li; Jihui Jia; Chunyan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 2.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 3.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

4.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

Review 5.  BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.

Authors:  Danilo Perrotti; Jason G Harb
Journal:  Leuk Lymphoma       Date:  2011-01-11

Review 6.  Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Authors:  Tomasz Skorski
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

7.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

Review 8.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Authors:  E K Thomas; J A Cancelas; Y Zheng; D A Williams
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

9.  Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

Authors:  Anna M Eiring; Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Ji Suk Chang; Mario Notari; William Willis; Carlo Gambacorti-Passerini; Stefano Volinia; Guido Marcucci; Michael A Caligiuri; Gustavo W Leone; Danilo Perrotti
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

10.  The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.

Authors:  Jamshid Sorouri Khorashad; Simon Wagner; Liat Greener; David Marin; Alistair Reid; Dragana Milojkovic; Hetal Patel; Shaun Willimott; Katy Rezvani; Gareth Gerrard; Sandra Loaiza; John Davis; John Goldman; Junia Melo; Jane Apperley; Letizia Foroni
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.